Trial Profile
Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 May 2017
Price :
$35
*
At a glance
- Drugs CN 105 (Primary)
- Indications Cerebral haemorrhage
- Focus Adverse reactions; First in man
- Sponsors CereNova
- 19 Dec 2016 Results published in the Journal of Clinical Pharmacology
- 16 Aug 2016 Status changed from recruiting to completed.
- 20 Feb 2016 New trial record